+

WO1986004145A1 - Modification de proteines avec peg - Google Patents

Modification de proteines avec peg Download PDF

Info

Publication number
WO1986004145A1
WO1986004145A1 PCT/US1985/002572 US8502572W WO8604145A1 WO 1986004145 A1 WO1986004145 A1 WO 1986004145A1 US 8502572 W US8502572 W US 8502572W WO 8604145 A1 WO8604145 A1 WO 8604145A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
modified
protein
polyethylene glycol
glycol
Prior art date
Application number
PCT/US1985/002572
Other languages
English (en)
Inventor
Thomas B. Tomasi
William L. Anderson
Original Assignee
University Of New Mexico
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of New Mexico filed Critical University Of New Mexico
Priority to GB08602672A priority Critical patent/GB2181433B/en
Publication of WO1986004145A1 publication Critical patent/WO1986004145A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/804—Radioisotope, e.g. radioimmunoassay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Definitions

  • the invention comprises a polyethylene glycol-protein derivative, and a method for preparing the derivative in excellent yields comprising covalently modifying the protein with polyethylene glycol (PEG) employing an active ester intermediate.
  • PEG polyethylene glycol
  • Derivatized antibodies are characterized by retained antigen binding activity, low binding capacity for cell surface Fc receptors, reduced immunogenicity, good storage stability, and non-toxicity, and are useful in conventional immunological techniques such as tumor imaging, chemotherapy, radiotherapy, and immunohistochemical procedures. It is contemplated that a broad range of diagnostic and therapeutic proteins, including monoclonal antibodies and enzymes, is modifiable by the process of the invention to provide modified proteins having reduced immunogenicity and low non-specific biological activity.
  • FIG. 1 represents SDS-disc gel electrophoresis of rabbit anti-conalbumin modified with the N-hydroxy-succinimide ester of mPEG succinate.
  • the gels were stained with coomassie blu and were scanned in a densitometer at 600nm.
  • the numbers in the figure correspond to the percentage of mPEG-modified amino groups.
  • FIG. 2 represents immunogenicity of 50 ug rabbit anti-CALB given up to Ha/ICR mice was evaluated using EIA titrations with a rabbit anti-mouse IgG-alkaline phosphatase reagent as the second step. Time of immunization is indicated with the arrow. The anti-rabbit IgG response elicited by unmodified rabbit anti-CALB is shown with the triangle. The response elicited PEG-modified (18% of amino groups) is shown by the circles.
  • FIG. 3 represents effect of mPEG-modification on the immunogenicity, of rabbit anti-conalbumin.
  • Swiss mice were immunized with 50 ⁇ g of antigen in PBS and the antibody response was evaluated using an enzyme immuno- assay.
  • Panel A depicts antibody titer 12 days following the primary immunization;
  • Panel B antibody titer 18 days following the primary immunizatio and three days following the secondary immunization;
  • Panel C the antibody titer 35 days following the primary immunization and 9 days following the tertiary immunization.
  • FIG. 4 represents effect of treatment with mPEG modified rabbit anti-conalbumin has on the antibody response to unmodified rabbit anti-conalbumin.
  • Swiss mice were either untreated (•) or immunized with 50 ⁇ g of nonimmunogenic mPEG ( ⁇ ) 5 and 20 days prior to the immunization with 50 ug of unmodified rabbit anti-conalbumin (Day 20).
  • Mouse anti-rabbit imrnunoglobulin titer was determined using an enzyme-linked assay.
  • FIG. 5 represents binding of immune complexes to P388.D1 cells.
  • Immune complexes were prepared from rabbit anti-conalbumin and fluorescein-labeled hen egg conalbumin (3 moles conalbumin/mole of antibody). An aliquot from each immune complex of 10 6 cells was incubated for 30 minutes with the concentration of immune complex shown on the abscissa. The number of fluorescent cells was determined by flow cytometry.
  • FIG. 6 represents binding of immune complexes prepared using 3 moles of fluorescein-labeled hen egg conalbumin and 1 mole of mPEG-modified rabbit anti-conalbumin to P388.D1 cells.
  • a 40 ug (determined from data in Figure 5) aliquot of each immune complex was incubated with 106 P388.D1 cell for 30 minutes. The number of fluorescent cells was determined by flow cytometry. The % mPEG modification was established by TNBS amino group analysis. Autofluorescence was observed in 17% of the cells. Different symbols depict experiments performed on different days with different samples of PEG-modified antibody.
  • FIG. 7 represents binding of fluorescein-labeled rabbit anti-mouse immunoglobulin ( ⁇ ) and mPEG-modified fluorescein-labeled affinity purified rabbit anti-mouse immunoglobulin (•) to 106 mouse splenocytes. Fluorescent cells were determined by flow cytometry. Panel A depicts the number of fluorescent cells as a function of antibody concentration. Panel B reports the number of cells in which fluorescence intensity was off scale on the flow cytometer.
  • FIG. 8 represents competitive inhibition of the binding of fluorescein-labeled rabbit anti-mouse immunoglobulin to mouse splenocytes.
  • Purified mouse IgG in the amount listed on the abscissa was incubated in the presence of either 8 uq fluorescein-labeled rabbit anti-mouse immunoglobulin ( ⁇ ) or 8 ⁇ g of the same reagent that was also mPEG-modified (•) and 1 x 10 6 murine splenocytes. Following washing the cells with PBS, the number of fluorescent cells was determined by flow cytometry. In this experiment, auto- fluorescence was seen in 8% of cells. With no added inhibito r mPEG-modif ied antibody detected 39% of cells and unmodified antibody 65%.
  • FIG. 9 represents effect of modification on fluorescence emission spectra of mPEG-modified, fluorescein- labeled antibody.
  • An affinity purified rabbit anti-mouse immunoglobulin reagent was modified with FITC to an F/P ratio of 3.7 (M).
  • a fraction of this reagent was modified with mPEG (30% of amino groups modified) and the fluorescence emission spectra of the mPEG-modified ( ⁇ ) and the unmodified (•) fluorescein-labeled antibody was determined at 0.80 mg/ml in a 0.30 cm cuvette using an AMINCO spectrofluorometer with an excitation wave length of 493 nm.
  • immunogenicity of foreign protein is reduced or eliminated by covalent modification of the protein with polyethylene glycol (PEG), employing a PEG active ester intermediate.
  • PEG modification of antibodies according to the process of the invention provides a derivative which retains avidity for antigen, while exhibiting reduced immunogenicity.
  • a particular advantage of the present invention is that a significant reduction in non-specific binding occurs, which is believed to be attributable to inactivation of the Fc portion of the antibody molecule. The process thus substantially eliminates oinding of the antibody to cell surface Fc receptors and promotes antibody concentration targeted tissue in applications such as tumor imaging and immunohistochemical techniques.
  • Particular PEG polymers useful in the process of the invention comprise substituted or unsubstituted PEG polymers having molecular weights of from about 1000 to 5000, which are themselves poor immunogens, and which can be coupled to protein using an active ester intermediate; the resulting modified protein must be biologically active and substantially non-toxic and non-immunogenic.
  • Monomethoxypolyethylene glycol (mPEG) satisfies these criteria, and is an especially suitable modifier, particularly for antibody.
  • Covalent mPEG modification of antibody molecule, using the present active ester approach, is accomplished with full retention of binding activity, and yields very predictable and reproducible modifications.
  • Protein modification according to the present invention occurs through covalent attachment of PEG to TNBS-available ( trinitrobenzene s ⁇ lfonic acid-available) amino groups on the protein molecule.
  • the immunogenicity of PEG-modified derivatives varies with the degree of modification, which is readily controlled by an appropriate selection of ratio of active ester to protein. At optimal ranges of derivatization (with typically about 10-20% of the available amino groups modified), most antibodies will not give rise to an immune response following exposure to the modified antibody in usual diagnostic and therapeutic amounts. At higher or lower degrees of modification, immunogenicity may be restored or even enhanced, depending upon the protein and the PEG modifier employed.
  • immunoglobulin molecules with between 13-18% of the amino groups modified with mPEG lack detectable immunogenicity; however, at either a lower or higher degree of modification, the mPEG-antibody complex may induce an immune response to the unmodified molecule and in many cases an enhancement of the antibody response is observed.
  • Antibody-mPEG derivatives of the present process retain full antigen binding activity with up to 35% of amino groups modified; since it has proved difficult to modify more than about 35% of available amino groups with mPEG using even a large excess of active ester, modification with mPEG is advantageously self-limiting in this respect. It is contemplated that most protein-mPEG derivatives having acceptably reduced immunogenicity will also retain effective antigen binding activity under the desired process conditions.
  • the degrees of modification mentioned are an average of this distribution. It is possible that the ranges are dependent upon the degree of purification, and, in particular, that acceptably reduced immunogenicity may be obtainable over a broader range of modification with increased purity of starting materials.
  • PEG is covalently attached to the protein molecule in accordance with the invention as follows:
  • PEG is carboxylated, and the purified product (PEG-COOH) esterified with a suitable carboxyl activating agent to form the active ester PEG*.
  • This active ester intermediate is then coupled to the protein molecule, with loss of the activating moiety.
  • the modification yields a distribution of protein molecules, variously modified with PEG; the product may more accurately be represented as Protein-(PEG) ⁇ wherein x is the number of PEG groups on the protein molecule.
  • Carboxylation of PEG to PEG-COOH and activation to the active ester intermediate PEG* is accomplished by any of several methods well-known in the art including methods employing carboxylating agents such as succinic anhydride, or classic textbook methods such as oxidation followed by the Williamson ether synthesis.
  • the selected PEG species is first succinylated with succinic anhydride to form PEG-COOH in step (1) of the reaction; PEG-COOH (succinylated) is then esterified with N-hydroxysuccinimide to form the active ester PEG* in step (2) of the reaction.
  • N-hydroxysuccinimide active ester is then reacted with the desired protein for form the PEG-Protein conjugate in step (3), with accompanying loss of the esterifying moiety.
  • Carboxyl-activating agents of the type useful for activating PEG-COOH are well-known in the art; in addition to N-hydroxysuccinimide, trinitrophenol is exemplary.
  • the process of the present invention provides an active, non-toxic product which retains biologic specificity but which has substantially lost non-specific reactivity.
  • the process of the present invention is applicable to a broad range of proteins to reduce the immunogenicity thereof when administered to a mammal, especially a human. While the process is particularly useful in reducing the immunogenicity of heterologous species proteins, the process is also applicable to homologous species proteins.
  • Antibodies are proteins of particular interest, as by the process of the invention, the specificity and avidity of the antibody molecules is retained, while non-specific binding of antibody molecules to cellular Fc receptor and rapid clearance of the antibody from the circulation is obviated.
  • Drugs, toxins, fluorescents, radionuclides, or other active moieties may readily be attached to the modified antibody molecule via the PEG substituent according to principles understood by those skilled in the art for delivery to selected tissue, especially to tumor tissue for diagnosis or therapy. Owing to the decreased non-specific activity of complexes comprising active moieties conjugated with PEG-modified antibody or other protein, premature dissociation of the complex is avoided, and highly selective delivery is achieved.
  • Monoclonal antibodies modified according to the invention also have increased with the present clinical use of unmodified HAbs of murine origin is the immune response of the host to the foreign protein, which both inactivates the MAb and has potential for the development of allergic reactions or serum sickness.
  • the clinical use of human monoclonal antibodies may partially obviate such an immune response; however, even human HAbs carry allotypic and idiotypic antigenic sites which can stimulate the response.
  • treatment with intact human MAb with an active moiety attached may be equivalent to immunizing with a hapten-conjugated protein which could provoke an antihapten response. Hodification of both human and animal MAbs according to the invention is thus particularly contemplated in eliminating all these immune responses.
  • modified antibodies of the invention are also useful in known tissue and cell staining procedures as substitutes for intact antibody to avoid non-specific staining owing to interaction between cellular Fc receptors and the Fc portion of the antibody.
  • Other proteins modifiable according to the invention include enzymes, especially enzymes clinically useful in replacement therapy.
  • the invention is applicable to proteins employed both in vitro and in vivo, wherein immunological procedures are hampered by immunogenicity of the protein and/or non-specific tissue binding.
  • Rabbit anti-conalbumin antisera was prepared by emulsifying hen egg conalbumin (Sigma, St. Louis, MO), dissolved in PBS with complete Freund's adjuvant (Gibco Laboratories, Grand Island, NY) at a final conalbumin concentration of 1.0 mg/ml. Rabbits were immunized in the footpads with a 1.0 ml aliquo t of the emulsion and boosted subcutaneously 12-14 days later with 1 mg emulsified antigen. Blood samples from the immunize rabbits were routinely monitored for antibody content by Ouchterlony analysis. Only high titer, late course, antisera was used for the remaining experiments.
  • the anti-conalbumin antibody was isolated from the rabbit antisera by affinity chromatography on a CM-Biogel A (Bio-Rad Laboratories, Richmond, CA) column which was coupled to conalbumin using the water soluble carbodimide procedure (BioRad Lab. Chem. Div., Tech. Bul. 1075, Richmond CA, 1980).
  • antisera was applied to the affinity column and the column was washed with 0.5 M sodium thio ⁇ yanate and the resulting antibody was simultaneously desalted and concentrated using a Micro Pro di Con apparatus, (Bio Moleculare Dynamics, Beaverton, OR).
  • the purified antibody was stored sterile at 4 degrees.
  • Antigen binding activity of the affinity purified and chemically modified antibodies was determined by evaluating their ability to competitively inhibit the binding of a rabbit anti-conalbumin-alkaline phosphatase conjugate to conalbumin-coated microelisa plates (Vangard, Neptune, NJ).
  • the enzyme linked antibody for this assay was prepared by a modification of the method described by Avermeas (Immuno. Chem. 6: 43, 1969) an to assure maximum sensitivity was titrated on the antigen coated plates prior to use in the assay.
  • the conalbumin coated microelisa plates were prepared by diluting conalbumin to 10 ⁇ g/ml in 0.05M NaHCO 3 , pH 9.6 and incubating for 18 hours at room temperature.
  • Immunogenicity of rabbit antibody and its PEG-modified derivatives were determined by measuring the antibody response of Swiss mice to an intraperitoneal injection of 50 ⁇ g of the antigen (rabbit antibody) in PBS.
  • the mouse antibody response was determined using a two step enzyme linked assay. In brief, several two-fold dilutions of mouse sera were incubated on a rabbit immunoglobulin coated microelisa plate for 2-5 hours. After extensive washing the plate was incubated with a rabbit anti-mouse alkaline phosphatase conjugate for an additional 2-5 hours.
  • mPEG succinate was lyophilized and dried in methylene chloride over molecular sieve 4A (Matheson Coleman & Bell, Norwood, OH). The mPEG succinate was then esterified in an equal molar mixture of DCC (Aldrich) and N-hydroxysuccinimide (Aldrich) and the resulting N-hydroxysuccinimide ester was recovered by petroleum ether precipitation.
  • the N-hydroxy- succinimide ester of mPEG succinate was purified by repeated recrystallization out of benzene with petroleum ether and was then dissolved in dry DMF and added with rapid mixing to a solution of antibody to be modified in 0.7 M, NaHCO 3 pH 9.6. The extent of modification was controlled by varying the active ester to antibody ratio. The resulting mPEG modified antibody was purified by exhaustive dialysis against PBS. Modification of Protein with FITC
  • the extent of the modification was established by both TNBS amino group analysis ( Analyt . Biochem. 14 : 328 , 1966 ) and by nonreduc ing SD S-gel electrophoresis on 6% polyacrylamide gels (Nature 227: 680, 1970).
  • Splenocytes were obtained from Swiss mice (Sprague-Dawley, Madison, WI) and the contaminating erythrocytes were analysed using the ammonium chloride technique (Mishell et al. Preparation of Mouse Cell Suspensions in Selected Methods of Cellular Immunology [B. Mishell and S. Shiigi, eds.] W. H. Freeman and Col., San Francisco, p. 23, 1980).
  • Ammonium chloride technique Mishell et al. Preparation of Mouse Cell Suspensions in Selected Methods of Cellular Immunology [B. Mishell and S. Shiigi, eds.] W. H. Freeman and Col., San Francisco, p. 23, 1980).
  • the murine macrophage line P388.D1 was grown in the laboratory from a strain initially acquired from the American Type Tissue Collection, Bethesda, Maryland.
  • EXAMPLE I Effect of mPEG modifications on antibody activity.
  • FIG. 5 The binding of immune complexes, prepared from rabbit anti-conalbumin antibody and fluorescein-labeled conalbumin to the murine macrophage P388.D1 cell line is shown in FIG. 5. These data show a concentration-dependent binding of the immune complexes to most cells in the population. This binding curve was not significantly altered v/hen immune complexes were prepared using several different antigen to antibody ratios.
  • FIG. 7 compares the titration curves of fluoresceinated rabbit antibody on mouse splenocytes prior to and following mPEG-modification. From this figure it can be seen that both reagents appear to be equally sensitive in detecting mouse B-cells (FIG. 7A).
  • the cells detected by mPEG-modified antibody appear to have an upper limit to the cellular fluorescence intensity whereas cells detected by the reagent that was not mPEG-modified show an increased fluorescence intensity (FIG. 7B) .
  • mouse immunoglobulin binds to cell surface immunoglobulin whereas the non mPEG-modified reagent exhibits nonspecific binding to cell surface Fc receptors.
  • purified mouse immunoglobulin was used to competitively inhibit the binding of both reagents to mouse splenocytes.
  • the amount of mouse immunoglobulin required to competitively inhibit the binding of the mPEG-modified reagent to mouse splenocytes was that concentration that would be predicted to be inhibitable based on theoretical binding calculations.
  • PEG-modified antibodies according to the invention exhibit markedly reduced immunogenicity, low specific binding capacity for cell surface Fc receptors, and retention of antigen-binding activity.
  • mPEG modification of antibodies also essentially eliminates Fc receptor binding.
  • Covalent modification of more than 15% of amino groups of rabbit anti-conalbumin antibody with mPEG completely prevented immune complexes prepared with this antibody from binding to the Fc receptor on the murine macrophage cell line, P388.D1. Similar sensitivities are observed for mPEG- modified fluorescein labelled antibodies since mPEG modification does not quench fluorescein fluorescence.
  • a fluorescein labelled rabbit anti-mouse immunoglobulin when modified with mPEG, exhibited no detectable binding to murine splenocyte Fc receptors by flow cytometry.
  • mPEG modification is a practical method of eliminating Fc binding for use in cell and tissue staining such as in immunohisto- chemical procedures and flow cytometry.
  • the lack of toxicity of PEG-modified protein in vivo suggests that it will also provide a method for decreasing background tissue binding as well as for reducing immunogenicity in the diagnostic and therapeutic uses of antibodies in humans.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Des molécules de protéines modifiées par PEG (polyéthylène glycol) caractérisées par une immunogénicité réduite sont préparées par modification covalente de la protéine avec PEG utilisant un intermédiaire d'ester actif. Des anticorps ainsi modifiés présentent une capacité de liaison diminuée pour des récepteurs en surface de cellules Fc, sont non toxiques et gardent une activité totale de liaison antigène, et sont par conséquent utiles dans une variété de procédures diagnostiques et thérapeutiques de type immunologique.
PCT/US1985/002572 1984-12-31 1985-12-31 Modification de proteines avec peg WO1986004145A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB08602672A GB2181433B (en) 1984-12-31 1985-12-31 Protein modification with peg

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US687,811 1984-12-31
US06/687,811 US4732863A (en) 1984-12-31 1984-12-31 PEG-modified antibody with reduced affinity for cell surface Fc receptors

Publications (1)

Publication Number Publication Date
WO1986004145A1 true WO1986004145A1 (fr) 1986-07-17

Family

ID=24761953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1985/002572 WO1986004145A1 (fr) 1984-12-31 1985-12-31 Modification de proteines avec peg

Country Status (5)

Country Link
US (1) US4732863A (fr)
JP (1) JPS62501449A (fr)
DE (2) DE3590392C2 (fr)
GB (1) GB2181433B (fr)
WO (1) WO1986004145A1 (fr)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254172A2 (fr) * 1986-07-24 1988-01-27 Miles Inc. Réactif à base d'anticorps marqué par une enzyme au moyen d'un groupe de liaison polyalkylèneglycol
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
EP0315456A2 (fr) * 1987-11-05 1989-05-10 Hybritech Incorporated Immunoglobulines modifiées au moyen d'un polysaccharide présentant un potentiel immunogène réduit ou des cinétiques pharmacologiques améliorées
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
FR2626373A1 (fr) * 1988-01-22 1989-07-28 Stabiligen Procede de preparation d'un traceur stable et traceur obtenu
EP0442372A1 (fr) * 1990-02-13 1991-08-21 Hoechst Aktiengesellschaft Haptènes marqués améliorés, leur procédé de préparation ainsi que l'utilisation de ces haptènes marqués en des essais immunologiques
EP0442724A2 (fr) * 1990-02-13 1991-08-21 Kirin-Amgen, Inc. IL-6 humaine modifiée
EP0473268A2 (fr) * 1990-07-23 1992-03-04 Zeneca Limited Compositions pharmaceutiques à libération continue comprenant un polypeptide conjugé de manière covalente à un polymère hydrosoluble
EP0496579A2 (fr) * 1991-01-23 1992-07-29 The General Hospital Corporation Immunogènes modifiés comportant un immunogène attaché à un ou plusieurs polymères non immunogéniques
EP0511600A2 (fr) * 1991-04-24 1992-11-04 Kuraray Co., Ltd. Ester d'acide carboximidique à longue chaîne
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
EP0584876A2 (fr) * 1992-08-27 1994-03-02 Sterling Winthrop Inc. Substances protéiniques contenant des oxides polyéthyléniques à faible taux diols et biologiquement actives
EP0470122B1 (fr) * 1989-04-27 1994-09-28 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Dispositif d'orientation de faisceau optique
WO1994022429A1 (fr) * 1993-03-31 1994-10-13 Liposome Technology, Inc. Procede de traitement d'une tumeur solide
EP0651646A1 (fr) * 1992-05-11 1995-05-10 Immunomedics, Inc. Conjugues therapeutiques de toxines et de medicaments
WO1995024429A1 (fr) * 1994-03-11 1995-09-14 Fidia Advanced Biopolymers S.R.L. Esters hautement reactifs de carboxy polysaccharides et nouveaux carboxy polysaccharides derives de ceux-ci
WO1996034015A1 (fr) * 1995-04-24 1996-10-31 Boehringer Ingelheim Pharmaceuticals, Inc. Anticorps anti-icam-1 modifies et leur utilisation dans le traitement des inflammations
WO1997028254A1 (fr) * 1996-02-01 1997-08-07 Biomedical Frontiers, Inc. Modulation antigenique de cellules
WO2000026230A1 (fr) * 1998-10-30 2000-05-11 Novozymes A/S Variants proteiques faiblement allergenes
US6103236A (en) * 1995-05-10 2000-08-15 Kyowa Hakko Kogyo Co., Ltd. Toxin conjugates
US6583267B2 (en) 1997-06-06 2003-06-24 Kyowa Hakko Kogyo Co., Ltd. Chemically modified polypeptides
US7811800B2 (en) 2005-04-11 2010-10-12 Savient Pharmaceuticals, Inc. Variant form of urate oxidase and use thereof
US8007784B1 (en) 1996-06-27 2011-08-30 Albany Medical College Antigenic modulation of cells
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US8188224B2 (en) 2005-04-11 2012-05-29 Savient Pharmaceuticals, Inc. Variant forms of urate oxidase and use thereof
US9534013B2 (en) 2006-04-12 2017-01-03 Horizon Pharma Rheumatology Llc Purification of proteins with cationic surfactant
US9885024B2 (en) 1998-08-06 2018-02-06 Duke University PEG-urate oxidase conjugates and use thereof
US9919031B2 (en) 2002-02-07 2018-03-20 The Board Of Trustees Of University Of Illinois Use of the insulin-like-growth factor 1 splice variant MGF for the prevention of myocardial damage
US10139399B2 (en) 2009-06-25 2018-11-27 Horizon Pharma Rheumatology Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525338A (en) * 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US5565519A (en) * 1988-11-21 1996-10-15 Collagen Corporation Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5620689A (en) * 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
SE468238B (sv) * 1990-02-28 1992-11-30 Sten Ohlson Laekemedel med svag affinitet
US5951972A (en) * 1990-05-04 1999-09-14 American Cyanamid Company Stabilization of somatotropins and other proteins by modification of cysteine residues
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5169627A (en) * 1991-10-28 1992-12-08 Mount Sinai School Of Medicine Of The City University Of New York Oral pharmaceutical composition containing a polyethylene glycol-immunoglobulin G conjugate for reconstitution of secretory immunity and method of reconstituting secretory immunity
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
US5846741A (en) * 1992-08-21 1998-12-08 Immunomedics, Inc. Boron neutron capture therapy using pre-targeting methods
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
CA2175578A1 (fr) * 1993-11-03 1995-05-11 Alec Sehon Regulation et suppression cellulaires
US6015897A (en) * 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
US5670132A (en) * 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
US6908903B1 (en) 1994-12-07 2005-06-21 Aletheon Pharmaceuticals, Inc. Cluster clearing agents
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
US6833408B2 (en) * 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
US7883693B2 (en) 1995-12-18 2011-02-08 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
US6458889B1 (en) 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
DK2111876T3 (da) * 1995-12-18 2011-12-12 Angiodevice Internat Gmbh Tværbundne polymerpræparater og fremgangsmåder til anvendelse deraf
US6321909B1 (en) 1997-02-13 2001-11-27 Sky High, Llc System for storing polyethylene glycol solutions
CN1297480A (zh) 1997-02-21 2001-05-30 基因技术股份有限公司 抗体片段－聚合物偶联物和人源化的抗白细胞介素－8单克隆抗体
US7122636B1 (en) * 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
DE19748489A1 (de) * 1997-11-03 1999-05-06 Roche Diagnostics Gmbh Polyethylenglykol-derivatisierte Biomoleküle und deren Verwendung in heterogenen Nachweisverfahren
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US7005504B2 (en) * 1998-01-22 2006-02-28 Genentech, Inc. Antibody fragment-peg conjugates
KR20010034697A (ko) 1998-03-26 2001-04-25 데이비드 엠 모이어 아미노산 치환을 갖는 세린 프로테아제 변이체
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
US6495136B1 (en) 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
EP1107998B1 (fr) 1998-08-28 2004-02-04 Gryphon Sciences Procede de fabrication de chaines polyamides de longueur definie et leur conjugues avec des proteines
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
WO2001007578A2 (fr) 1999-07-22 2001-02-01 The Procter & Gamble Company Proteases variantes de la subtilisine par substitutions acide amine dans des regions definies de l'epitope
MXPA02000842A (es) 1999-07-22 2002-07-30 Procter & Gamble Conjugados de proteasa que tienen sitios de corte protegidos estericamente.
MXPA02000843A (es) 1999-07-22 2002-07-30 Procter & Gamble Variantes de subtilisina proteasa que tienen supresiones de aminoacidos y sustituciones en regiones de epitope definidas.
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
AU7445900A (en) * 1999-09-27 2001-04-30 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
US7067111B1 (en) * 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
WO2001038352A2 (fr) 1999-11-24 2001-05-31 Schering Corporation Procedes d'inhibition de metastases
EP2389943A1 (fr) 2000-04-18 2011-11-30 Schering Corporation Utilisation d'antagonistes IL-174 pour traiter les liées aux Th2
BRPI0111220B8 (pt) * 2000-06-02 2021-07-27 Univ Texas conjugados de fármacos com etilenodicisteína (ec)
AU2001268228A1 (en) 2000-06-08 2001-12-17 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
ATE513563T1 (de) * 2000-10-09 2011-07-15 Isis Innovation Therapeutische und toleranz-induzierende antikörper
CA2444383A1 (fr) * 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Compositions therapeutiques conjuguees agent/ligand, leur methodes de synthese et leur utilisation
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
ES2399503T5 (es) 2002-02-01 2021-04-08 Merck Sharp & Dohme Uso de reactivos relacionados con citocinas de mamíferos
PL216223B1 (pl) 2002-03-13 2014-03-31 Biogen Idec Inc Przeciwciało przeciwko integrynom α<sub>v</sub>β<sub>6</sub>, jego fragment wiążący antygen, zawierająca je kompozycja i ich zastosowanie, komórka hybrydoma oraz sposób wykrywania α<sub>v</sub>β<sub>6</sub> in vitro
US7452533B2 (en) * 2002-03-26 2008-11-18 Biosynexus Incorporated Antimicrobial polymer conjugate containing lysostaphin and polyethylene glycol
CN101985443A (zh) * 2002-11-07 2011-03-16 得克萨斯大学体系董事会 乙二半胱氨酸（ec）-药物结合物、组合物及用于组织特异性疾病显像的方法
ATE515514T1 (de) 2002-12-23 2011-07-15 Schering Corp Verwendungen von säuger-cytokin il-23 ; verwandte reagenzien
GEP20084487B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof
DK1667708T5 (da) * 2002-12-26 2012-11-12 Mountain View Pharmaceuticals Polyethylenglycolkonjugater af interferon-beta-1b med forøget biologisk styrke in vitro
WO2004060405A2 (fr) * 2002-12-30 2004-07-22 Angiotech International Ag Composes et compositions reagissant avec des tissus et utilisations associees
EP2181704B1 (fr) * 2002-12-30 2015-05-06 Angiotech International Ag Liberation de médicaments a partir d'une composition polymère à gélification rapide
KR100988129B1 (ko) * 2003-04-30 2010-10-18 쥬리디컬 파운데이션 더 케모-세로-쎄라퓨틱 리서치 인스티튜트 인간 항인간 인터루킨-18 항체와 그 단편, 및 이들의이용방법
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
KR100974733B1 (ko) 2004-04-28 2010-08-06 안지오디바이스 인터내셔널 게엠베하 가교된 생합성물질을 형성하기 위한 조성물 및 시스템, 및이와 관련된 제조 및 사용 방법
EP1789437A4 (fr) * 2004-07-30 2008-11-05 Sinai School Medicine Inhibiteurs de npc1l1 et npc1l1 et procédés d'utilisation associés
CA2581093C (fr) 2004-09-17 2014-11-18 Angiotech Biomaterials Corporation Composes multifonctionels pour la formation de biomateriaux reticules et leurs procedes de preparation et d'utilisation
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
JP2008541015A (ja) * 2005-04-28 2008-11-20 ベンタナ・メデイカル・システムズ・インコーポレーテツド ナノ粒子コンジュゲート
EP3144675A1 (fr) 2005-04-28 2017-03-22 Ventana Medical Systems, Inc. Enzymes conjuguées à des anticorps via un lieur peg hétérobifontionnel
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
WO2007058129A1 (fr) * 2005-11-18 2007-05-24 Nitto Boseki Co., Ltd. Procede de dosage d'un antigene et kit utilisable dans le procede
EP2963011B1 (fr) 2005-11-23 2018-05-09 Ventana Medical Systems, Inc. Conjugué moléculaire
CU23556A1 (es) 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
JP2009533347A (ja) 2006-04-07 2009-09-17 ネクター セラピューティックス エイエル，コーポレイション 抗ＴＮＦα抗体の複合体
US8758723B2 (en) 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
WO2010078376A2 (fr) * 2008-12-30 2010-07-08 Ventana Medical Systems, Inc. Anticorps conjugués à un polymère spécifiques de fc et leur utilisation en diagnostic
RU2636046C2 (ru) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
US10584181B2 (en) 2009-12-04 2020-03-10 Genentech, Inc. Methods of making and using multispecific antibody panels and antibody analog panels
US20130137645A1 (en) * 2010-07-19 2013-05-30 Mary S. Rosendahl Modified peptides and proteins
JP6279902B2 (ja) * 2010-10-18 2018-02-14 ユニバーシティ オブ ワシントン センター フォー コマーシャライゼーション 発色団ポリマードット
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
WO2014144466A1 (fr) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anticorps anti-alpha ν bêta 6 et leurs utilisations
KR20150133576A (ko) * 2014-05-20 2015-11-30 삼성전자주식회사 화학적 개질된 표적화 단백질 및 그의 이용
US10632180B2 (en) 2015-02-06 2020-04-28 The Regents Of The University Of California Methods and compositions for improved cognition
CN111278461A (zh) 2017-08-16 2020-06-12 百时美施贵宝公司 可前药化抗体、其前药以及使用和制备方法
US20220118060A1 (en) 2019-02-04 2022-04-21 The Regents Of The University Of California Exercise-induced circulatory factors for amelioration of cognitive, neurological, and regenerative dysfunction during aging
US20220251206A1 (en) 2019-06-11 2022-08-11 Bristol-Myers Squibb Company Anti-ctla4 antibody prodruggable (probody) at a cdr position
CN110672836B (zh) * 2019-09-30 2023-03-21 香港大德昌龙生物科技有限公司 磁珠包被物及其制备方法和应用、检测试剂盒
WO2024092238A1 (fr) 2022-10-28 2024-05-02 Unity Biotechnology, Inc. Polypeptide ou polynucléotide klotho pour améliorer la cognition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4495285A (en) * 1981-10-30 1985-01-22 Kimihiro Shimizu Plasminogen activator derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1064396A (fr) * 1975-02-18 1979-10-16 Myer L. Coval Precipitation fractionnee de la gamma globuline a l'aide de polyethylene glycol
DE2856939A1 (de) * 1978-12-13 1980-07-03 Schura Blutderivate Gmbh & Co Verfahren zur gewinnung von intravenoes-vertraeglichen gammaglobulinen
JPS56113713A (en) * 1980-02-14 1981-09-07 Chemo Sero Therapeut Res Inst Preparation of immunoglobulin with high content of monomer
JPS56163456A (en) * 1980-05-21 1981-12-16 Otsuka Pharmaceut Co Ltd Preparation of antigen
US4427653A (en) * 1981-01-26 1984-01-24 President And Fellows Of Harvard College Method of making monoclonal antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4495285A (en) * 1981-10-30 1985-01-22 Kimihiro Shimizu Plasminogen activator derivatives
US4495285B1 (fr) * 1981-10-30 1986-09-23 Nippon Chemiphar Co

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, Vol. 98; No. 3, issued 1983, January 17, A.W. Richter et al:, "Antibodies against polyethylene glycol....," page 394, Column 1, the abstract No. 98:15249k; & Int. Arch. Allergy Appl. Immunol., 1983, Vol. 70, No. 2, pages 124-31 *
Z. Naturforsch., Section C, Vol. 38c, No.1/2, issued January/February 1983, E. Boccu et al:, "Coupling of Monomethoxypolyethylencglycols to Proteins via Active Esters", pages 94-99 *

Cited By (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
EP0254172A2 (fr) * 1986-07-24 1988-01-27 Miles Inc. Réactif à base d'anticorps marqué par une enzyme au moyen d'un groupe de liaison polyalkylèneglycol
EP0254172A3 (en) * 1986-07-24 1989-01-18 Miles Inc. Enzyme-labeled antibody reagent with polyalkyleneglycol linking group
EP0315456A2 (fr) * 1987-11-05 1989-05-10 Hybritech Incorporated Immunoglobulines modifiées au moyen d'un polysaccharide présentant un potentiel immunogène réduit ou des cinétiques pharmacologiques améliorées
EP0315456A3 (en) * 1987-11-05 1990-03-28 Hybritech Incorporated Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
FR2626373A1 (fr) * 1988-01-22 1989-07-28 Stabiligen Procede de preparation d'un traceur stable et traceur obtenu
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
EP0470122B1 (fr) * 1989-04-27 1994-09-28 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Dispositif d'orientation de faisceau optique
EP0442724A3 (en) * 1990-02-13 1992-02-26 Kirin-Amgen, Inc. Modified hil-6
EP0442724A2 (fr) * 1990-02-13 1991-08-21 Kirin-Amgen, Inc. IL-6 humaine modifiée
EP0442372A1 (fr) * 1990-02-13 1991-08-21 Hoechst Aktiengesellschaft Haptènes marqués améliorés, leur procédé de préparation ainsi que l'utilisation de ces haptènes marqués en des essais immunologiques
EP0473268A2 (fr) * 1990-07-23 1992-03-04 Zeneca Limited Compositions pharmaceutiques à libération continue comprenant un polypeptide conjugé de manière covalente à un polymère hydrosoluble
EP0473268A3 (en) * 1990-07-23 1992-09-16 Imperial Chemical Industries Plc Continuous release pharmaceutical compositions comprising a polypeptide covalently conjugated to a water soluble polymer
US5773581A (en) * 1990-07-23 1998-06-30 Zeneca Limited Conjugate of a solution stable G-CSF derivative and a water-soluble polymer
US5320840A (en) * 1990-07-23 1994-06-14 Imperial Chemical Industries Plc Continuous release pharmaceutical compositions
EP0496579A2 (fr) * 1991-01-23 1992-07-29 The General Hospital Corporation Immunogènes modifiés comportant un immunogène attaché à un ou plusieurs polymères non immunogéniques
EP0496579A3 (en) * 1991-01-23 1992-09-02 The General Hospital Corporation Modified immunogens comprising an immunogen attached to one or more non-immunogenic polymers
US5885570A (en) * 1991-01-23 1999-03-23 The General Hospital Corporation Induction of tolerance with modified immunogens
EP0511600A3 (en) * 1991-04-24 1993-01-20 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
US5336782A (en) * 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
EP0511600A2 (fr) * 1991-04-24 1992-11-04 Kuraray Co., Ltd. Ester d'acide carboximidique à longue chaîne
US5414089A (en) * 1991-04-24 1995-05-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
USRE36359E (en) * 1991-04-24 1999-10-26 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
EP0651646B1 (fr) * 1992-05-11 2003-09-03 Immunomedics, Inc. Conjugues therapeutiques de toxines et de medicaments
EP0651646A1 (fr) * 1992-05-11 1995-05-10 Immunomedics, Inc. Conjugues therapeutiques de toxines et de medicaments
EP0584876A2 (fr) * 1992-08-27 1994-03-02 Sterling Winthrop Inc. Substances protéiniques contenant des oxides polyéthyléniques à faible taux diols et biologiquement actives
AU675798B2 (en) * 1992-08-27 1997-02-20 Sanofi Low diol polyalkylene oxide biologically active proteinaceous substances
EP0584876A3 (en) * 1992-08-27 1994-06-29 Sterling Winthrop Inc Low diol polyalkylene oxide biologically active proteinaceous substances
WO1994022429A1 (fr) * 1993-03-31 1994-10-13 Liposome Technology, Inc. Procede de traitement d'une tumeur solide
WO1995024429A1 (fr) * 1994-03-11 1995-09-14 Fidia Advanced Biopolymers S.R.L. Esters hautement reactifs de carboxy polysaccharides et nouveaux carboxy polysaccharides derives de ceux-ci
WO1996034015A1 (fr) * 1995-04-24 1996-10-31 Boehringer Ingelheim Pharmaceuticals, Inc. Anticorps anti-icam-1 modifies et leur utilisation dans le traitement des inflammations
US6638509B1 (en) 1995-05-10 2003-10-28 Kyowa Hakko Kogyo, Co., Ltd. Toxin conjugates
US6103236A (en) * 1995-05-10 2000-08-15 Kyowa Hakko Kogyo Co., Ltd. Toxin conjugates
JP2000505423A (ja) * 1996-02-01 2000-05-09 バイオメディカル フロンティアーズ インコーポレイテッド 細胞の抗原による免疫調整
WO1997028254A1 (fr) * 1996-02-01 1997-08-07 Biomedical Frontiers, Inc. Modulation antigenique de cellules
US8007784B1 (en) 1996-06-27 2011-08-30 Albany Medical College Antigenic modulation of cells
US6583267B2 (en) 1997-06-06 2003-06-24 Kyowa Hakko Kogyo Co., Ltd. Chemically modified polypeptides
US7547675B2 (en) 1997-06-06 2009-06-16 Kyowa Hakko Kirin Co., Ltd. Chemically modified polypeptides
US9885024B2 (en) 1998-08-06 2018-02-06 Duke University PEG-urate oxidase conjugates and use thereof
WO2000026230A1 (fr) * 1998-10-30 2000-05-11 Novozymes A/S Variants proteiques faiblement allergenes
US9919031B2 (en) 2002-02-07 2018-03-20 The Board Of Trustees Of University Of Illinois Use of the insulin-like-growth factor 1 splice variant MGF for the prevention of myocardial damage
US9670467B2 (en) 2005-04-11 2017-06-06 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
US9926538B2 (en) 2005-04-11 2018-03-27 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
US8178334B2 (en) 2005-04-11 2012-05-15 Savient Pharmaceuticals, Inc. Variant form of urate oxidase and use thereof
US8188224B2 (en) 2005-04-11 2012-05-29 Savient Pharmaceuticals, Inc. Variant forms of urate oxidase and use thereof
US8293228B2 (en) 2005-04-11 2012-10-23 Savient Pharmaceuticals Inc. Variant form of urate oxidase and use thereof
US8465735B2 (en) 2005-04-11 2013-06-18 Savient Pharmaceuticals, Inc. Variant form of urate oxidase and use thereof
US8541205B2 (en) 2005-04-11 2013-09-24 Savient Pharmaceuticals, Inc. Variant forms of urate oxidase and use thereof
US9017980B2 (en) 2005-04-11 2015-04-28 Crealta Pharmaceuticals Llc Variant forms of urate oxidase and use thereof
US11781119B2 (en) 2005-04-11 2023-10-10 Horizon Therapeutics Usa, Inc. Variant forms of urate oxidase and use thereof
US8034594B2 (en) 2005-04-11 2011-10-11 Savient Pharmaceuticals, Inc. Variant form of urate oxidase and use thereof
US7964381B2 (en) 2005-04-11 2011-06-21 Savient Pharmaceuticals, Inc. Variant form of urate oxidase and use thereof
US7811800B2 (en) 2005-04-11 2010-10-12 Savient Pharmaceuticals, Inc. Variant form of urate oxidase and use thereof
US9926537B2 (en) 2005-04-11 2018-03-27 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US11345899B2 (en) 2005-04-11 2022-05-31 Horizon Therapeutics Usa, Inc. Variant forms of urate oxidase and use thereof
US10160958B2 (en) 2005-04-11 2018-12-25 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
US10731139B2 (en) 2005-04-11 2020-08-04 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
US9534013B2 (en) 2006-04-12 2017-01-03 Horizon Pharma Rheumatology Llc Purification of proteins with cationic surfactant
US10823727B2 (en) 2009-06-25 2020-11-03 Horizon Pharma Rheumatology Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
US10139399B2 (en) 2009-06-25 2018-11-27 Horizon Pharma Rheumatology Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
US11598767B2 (en) 2009-06-25 2023-03-07 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
US11639927B2 (en) 2009-06-25 2023-05-02 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
US11982670B2 (en) 2009-06-25 2024-05-14 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
US12188927B2 (en) 2009-06-25 2025-01-07 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Also Published As

Publication number Publication date
GB8602672D0 (en) 1986-03-12
DE3590392T (fr) 1988-10-27
GB2181433B (en) 1989-01-05
JPH0576960B2 (fr) 1993-10-25
US4732863A (en) 1988-03-22
GB2181433A (en) 1987-04-23
DE3590392C2 (fr) 1993-01-14
JPS62501449A (ja) 1987-06-11

Similar Documents

Publication Publication Date Title
US4732863A (en) PEG-modified antibody with reduced affinity for cell surface Fc receptors
Fuks et al. Carcinoembryonic antigen (CEA): Molecular biology and clinical significance
US4478744A (en) Method of obtaining antibodies
EP0111211B1 (fr) Immunoessai pour protéines et fragments de protéines non enzymatiquement glucosylés - un indice de la glycémie
AU619827B2 (en) Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
EP0005271A2 (fr) Méthode et trousse pour essai immunologique enzymatique de substances biologiques
US4882423A (en) Substance-conjugated complement component C1q
US5035995A (en) Test method involving substance-conjugated complement component C1q
SU1331433A3 (ru) Способ получени сопр женных соединений гаптенов и мурамилпептидов
Lowey et al. An immunochemical approach to the structure of myosin and the thick filament
Braun et al. Antigenic determinants of murein lipoprotein and its exposure at the surface of Enterobacteriaceae
Kauffman et al. Standardization of allergenic extracts of Aspergillus fumigatus: liberation of IgE-binding components during cultivation
FI95579C (fi) Immunologinen menetelmä intaktin prokollageenipeptidin (tyyppi III) ja prokollageenin (tyyppi III) määrittämiseksi selektiivisesti elimistönesteistä ja väline sen toteuttamiseksi
JPS6259783B2 (fr)
Kochoumian et al. Immunochemical studies of dextran coupled ragweed pollen allergen, antigen E
Delpech et al. An antigen associated with mesenchyme in human tumours that cross-reacts with brain glycoprotein
SCHALLER et al. Enzyme‐linked immunosorbent assay for the neuropeptide ‘head activator’
Prasad et al. Detection of antimicrofilarial ES antigen-antibody in immune complexes in Bancroftian filariasis by enzyme immunoassay
Boctor et al. Immunoaffinity fractionation of Schistosoma mansoni worm antigens using human antibodies and its application for serodiagnosis
US6306608B1 (en) Anti-human LECT2 antibody, cells producing the same, and method and kit for assaying the same
Layton Anti-carbohydrate activity of T cell-reactive chicken anti-mouse immunoglobulin antibodies.
Henslee et al. Identification and characterization of new antigenic fragments related to carcinoembryonic antigen in adult feces
EP0137822B1 (fr) Anticorps specifique de la forme native de 2&#39;, 5&#39;-oligonucleotides, son procede de preparation et son utilisation comme produit reactif lors d&#39;analyses immunologiques ou pour lier des 2&#39;, 5&#39;-oligonucleotides en systemes biologiques
Stålenheim PROTEIN A FROM ST APHYLOCOCCUS AUREUS XI: Fixation of Human Complement and of Complement from Guinea Pig and Rabbit
Heidelberger Protein constitution and immunological behavior

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): DE GB JP

RET De translation (de og part 6b)

Ref document number: 3590392

Country of ref document: DE

Date of ref document: 19881027

WWE Wipo information: entry into national phase

Ref document number: 3590392

Country of ref document: DE

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载